Lunai Bioworks Inc (LNAI)

$0.99 -0.01 (-0.62%)
Market Cap 23.25M
Revenue (ttm) 0.00
Net Income (ttm) -178.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 32,400
Avg Vol 4,845,248
Day's Range N/A - N/A
Shares Out 23.43M
Stochastic %K 12%
Beta 0.37
Analysts Strong Buy
Price Target N/A

Company Profile

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 918 1980
Address:
2080 Century Park East, Suite 906, Los Angeles, United States
PeriodPulse
PeriodPulse Dec. 25 at 5:21 PM
$LNAI Market behavior suggests the name is transitioning from speculation toward proof‑based evaluation. Margin stability needs to accompany any growth acceleration. Consistent milestones could shift perception faster than fundamentals alone. Patience is reasonable — but it must be matched by tangible progress.
0 · Reply
11thestate
11thestate Dec. 25 at 4:11 PM
$LNAI $ENOB has agreed to settle with investors over claims that it misled them by concealing its co-founder’s lack of proper credentials and criminal history. Who’s eligible? Anyone who purchased $ENOB shares between January 17, 2018 and June 27, 2022. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.09 — but if only ~25% of eligible investors file, the effective payout could increase to $0.36. Can I still file? Yes — claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/enochian-biosciences-investor-settlement
0 · Reply
G1992
G1992 Dec. 22 at 1:05 AM
$LNAI is partnership high possibility??
2 · Reply
Manny2284
Manny2284 Dec. 20 at 2:48 AM
$WOK $LNAI $PBM $INHD 👌😇☝️
1 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Dec. 19 at 2:20 PM
🌅 Watchlist part 2 ✅ $AIIO mid $0.50 support; if above $0.60, has potential to $0.70 / $0.80 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $LNAI • $RUBI still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D
0 · Reply
Stengaard1
Stengaard1 Dec. 18 at 4:47 PM
$LNAI Lunai is featured in an article in International Business Times. In addition to analysing the market potential of the sizzling hot Parkinson/Epilepsy/Alzheimer's market, IBT also examined several of the company-specific dynamics that influence investor decisions, such as: Approximately 11 million shares sold short against a post-split public float of roughly 23 million shares (This far exceeds my calculation and numbers, but it also explains why, despite all the recent good news, the price has been hammered. Some Investors will undoubtedly view this large number as negative - assuming that shortsellers are rational decision makers - others see this as a squeeze opportunity, if LNAI up their game.) A market capitalisation reset from over $350 million to under $30S million during 2025 (If you have close to 50% of shares shorted it is understandable - especially if on top of the official 1.4 million) The potential for valuation re-rating as partnership discussions advance (Deerfield have entered partnerships with Biosymetrics in other cases - they might have a right of first refusal ?) Seasonal year-end portfolio positioning effects read it all here: https://www.nasdaq.com/press-release/lunai-bioworks-nasdaq-lnai-featured-international-business-times-ai-partnership-talk
1 · Reply
DD_First
DD_First Dec. 17 at 3:07 PM
$LNAI As of late 2025, Lunai Bioworks (NASDAQ: LNAI) has reported several significant breakthroughs in its AI-powered therapeutic and diagnostic pipelines: Parkinson's Disease Subtyping: In December 2025, Lunai announced the identification of three clinically relevant subtypes of Parkinson's disease using its proprietary Augusta Platform, which integrates large-scale proteomic data to prioritize drug targets, aiming to accelerate clinical trials in a $13 billion market. LNAI achieved complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models using its second-generation immune cell therapy. First Licensing LOI: Following the pancreatic cancer results, Lunai secured its first Letter of Intent to license its next-generation immune cell therapy. Alzheimer’s Diagnostic Improvement: In October 2025, Lunai's AI platform showed a 35% improvement in diagnostic accuracy for Alzheimer's disease by combining MRI scans with genetic and metabolic data.
0 · Reply
11thestate
11thestate Dec. 17 at 2:50 PM
$LNAI has reached a 2.5M settlement with $ENOB investors over claims that it concealed its co-founder’s lack of proper credentials and criminal history. The filing deadline is December 7, 2025. If you bought $ENOB between January 17, 2018 and June 27, 2022, you can file for payment here: https://11th.com/cases/enochian-biosciences-investor-settlement
0 · Reply
1dk2la
1dk2la Dec. 17 at 3:45 AM
$LNAI further good news on its way .............?
0 · Reply
1dk2la
1dk2la Dec. 16 at 7:26 PM
$LNAI
0 · Reply
Latest News on LNAI
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance

Dec 18, 2025, 9:00 AM EST - 7 days ago

Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

Dec 9, 2025, 7:45 AM EST - 16 days ago

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

Nov 25, 2025, 7:45 AM EST - 4 weeks ago

Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

Nov 5, 2025, 9:22 AM EST - 7 weeks ago

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds

Oct 30, 2025, 9:32 AM EDT - 2 months ago

Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds

Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics

Oct 16, 2025, 9:45 AM EDT - 2 months ago

Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics

Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

Oct 16, 2025, 9:15 AM EDT - 2 months ago

Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline

Oct 6, 2025, 9:15 AM EDT - 2 months ago

Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline

Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense

Sep 30, 2025, 9:15 AM EDT - 3 months ago

Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense

Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

Sep 25, 2025, 8:30 AM EDT - 3 months ago

Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

Sep 24, 2025, 4:50 PM EDT - 3 months ago

Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics

Sep 11, 2025, 7:00 AM EDT - 3 months ago

Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics

Top 3 Health Care Stocks You'll Regret Missing In Q3

Sep 9, 2025, 9:12 AM EDT - 3 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

SMMT

Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery

Sep 9, 2025, 8:47 AM EDT - 3 months ago

Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery

Lunai Bioworks Strengthens European Strategy Through Restructuring

Sep 8, 2025, 8:50 AM EDT - 3 months ago

Lunai Bioworks Strengthens European Strategy Through Restructuring

Lunai Bioworks Inc. Retains American Defense International

Sep 4, 2025, 10:05 AM EDT - 4 months ago

Lunai Bioworks Inc. Retains American Defense International

Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics

Aug 27, 2025, 9:45 AM EDT - 4 months ago

Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics

Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

Aug 8, 2025, 10:45 AM EDT - 4 months ago

Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

Jul 28, 2025, 10:38 AM EDT - 5 months ago

Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

Jul 17, 2025, 9:15 AM EDT - 5 months ago

Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

Jul 9, 2025, 8:00 AM EDT - 6 months ago

Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

Jun 30, 2025, 9:21 AM EDT - 6 months ago

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

Jun 3, 2025, 9:15 AM EDT - 7 months ago

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 22, 2025, 3:12 PM EDT - 7 months ago

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 22, 2025, 11:05 AM EDT - 7 months ago

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

May 14, 2025, 9:15 AM EDT - 8 months ago

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

May 13, 2025, 9:15 AM EDT - 8 months ago

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

Apr 22, 2025, 9:20 AM EDT - 8 months ago

Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Apr 9, 2025, 9:25 AM EDT - 9 months ago

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Apr 4, 2025, 9:40 AM EDT - 9 months ago

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Mar 3, 2025, 9:15 AM EST - 10 months ago

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Feb 26, 2025, 1:25 PM EST - 10 months ago

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Renovaro Announces $15 million in Equity Committed

Feb 26, 2025, 9:15 AM EST - 10 months ago

Renovaro Announces $15 million in Equity Committed

PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI

Jan 7, 2025, 6:51 PM EST - 1 year ago

PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI

Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Jan 7, 2025, 9:15 AM EST - 1 year ago

Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Renovaro Issues Shareholder Letter and Provides Corporate Update

Jan 7, 2025, 9:15 AM EST - 1 year ago

Renovaro Issues Shareholder Letter and Provides Corporate Update

Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Jan 6, 2025, 9:15 AM EST - 1 year ago

Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Dec 30, 2024, 9:00 AM EST - 1 year ago

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program

Dec 23, 2024, 9:00 AM EST - 1 year ago

RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program

Renovaro Regains Compliance with NASDAQ Listing Requirement

Dec 20, 2024, 3:40 PM EST - 1 year ago

Renovaro Regains Compliance with NASDAQ Listing Requirement

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

Dec 20, 2024, 9:00 AM EST - 1 year ago

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing

Oct 17, 2024, 9:15 AM EDT - 1 year ago

RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing

Renovaro Announces Strategic Restructuring and Leadership Transition

Oct 16, 2024, 9:28 AM EDT - 1 year ago

Renovaro Announces Strategic Restructuring and Leadership Transition

RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress

Sep 13, 2024, 9:00 AM EDT - 1 year ago

RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress

RenovaroCube Announces Strategic Offering of Up to 20% Ownership

Sep 11, 2024, 9:15 AM EDT - 1 year ago

RenovaroCube Announces Strategic Offering of Up to 20% Ownership

Renovaro, Inc. Announces $10 million in Equity Committed

Jun 14, 2024, 9:06 AM EDT - 1 year ago

Renovaro, Inc. Announces $10 million in Equity Committed

Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

May 24, 2024, 9:20 AM EDT - 1 year ago

Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

May 21, 2024, 8:39 AM EDT - 1 year ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

BAX RAPT SAGE TMCI

Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

Apr 30, 2024, 11:00 AM EDT - 1 year ago

Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership

Apr 24, 2024, 9:00 AM EDT - 1 year ago

RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership

PeriodPulse
PeriodPulse Dec. 25 at 5:21 PM
$LNAI Market behavior suggests the name is transitioning from speculation toward proof‑based evaluation. Margin stability needs to accompany any growth acceleration. Consistent milestones could shift perception faster than fundamentals alone. Patience is reasonable — but it must be matched by tangible progress.
0 · Reply
11thestate
11thestate Dec. 25 at 4:11 PM
$LNAI $ENOB has agreed to settle with investors over claims that it misled them by concealing its co-founder’s lack of proper credentials and criminal history. Who’s eligible? Anyone who purchased $ENOB shares between January 17, 2018 and June 27, 2022. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.09 — but if only ~25% of eligible investors file, the effective payout could increase to $0.36. Can I still file? Yes — claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/enochian-biosciences-investor-settlement
0 · Reply
G1992
G1992 Dec. 22 at 1:05 AM
$LNAI is partnership high possibility??
2 · Reply
Manny2284
Manny2284 Dec. 20 at 2:48 AM
$WOK $LNAI $PBM $INHD 👌😇☝️
1 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Dec. 19 at 2:20 PM
🌅 Watchlist part 2 ✅ $AIIO mid $0.50 support; if above $0.60, has potential to $0.70 / $0.80 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $LNAI • $RUBI still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D
0 · Reply
Stengaard1
Stengaard1 Dec. 18 at 4:47 PM
$LNAI Lunai is featured in an article in International Business Times. In addition to analysing the market potential of the sizzling hot Parkinson/Epilepsy/Alzheimer's market, IBT also examined several of the company-specific dynamics that influence investor decisions, such as: Approximately 11 million shares sold short against a post-split public float of roughly 23 million shares (This far exceeds my calculation and numbers, but it also explains why, despite all the recent good news, the price has been hammered. Some Investors will undoubtedly view this large number as negative - assuming that shortsellers are rational decision makers - others see this as a squeeze opportunity, if LNAI up their game.) A market capitalisation reset from over $350 million to under $30S million during 2025 (If you have close to 50% of shares shorted it is understandable - especially if on top of the official 1.4 million) The potential for valuation re-rating as partnership discussions advance (Deerfield have entered partnerships with Biosymetrics in other cases - they might have a right of first refusal ?) Seasonal year-end portfolio positioning effects read it all here: https://www.nasdaq.com/press-release/lunai-bioworks-nasdaq-lnai-featured-international-business-times-ai-partnership-talk
1 · Reply
DD_First
DD_First Dec. 17 at 3:07 PM
$LNAI As of late 2025, Lunai Bioworks (NASDAQ: LNAI) has reported several significant breakthroughs in its AI-powered therapeutic and diagnostic pipelines: Parkinson's Disease Subtyping: In December 2025, Lunai announced the identification of three clinically relevant subtypes of Parkinson's disease using its proprietary Augusta Platform, which integrates large-scale proteomic data to prioritize drug targets, aiming to accelerate clinical trials in a $13 billion market. LNAI achieved complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models using its second-generation immune cell therapy. First Licensing LOI: Following the pancreatic cancer results, Lunai secured its first Letter of Intent to license its next-generation immune cell therapy. Alzheimer’s Diagnostic Improvement: In October 2025, Lunai's AI platform showed a 35% improvement in diagnostic accuracy for Alzheimer's disease by combining MRI scans with genetic and metabolic data.
0 · Reply
11thestate
11thestate Dec. 17 at 2:50 PM
$LNAI has reached a 2.5M settlement with $ENOB investors over claims that it concealed its co-founder’s lack of proper credentials and criminal history. The filing deadline is December 7, 2025. If you bought $ENOB between January 17, 2018 and June 27, 2022, you can file for payment here: https://11th.com/cases/enochian-biosciences-investor-settlement
0 · Reply
1dk2la
1dk2la Dec. 17 at 3:45 AM
$LNAI further good news on its way .............?
0 · Reply
1dk2la
1dk2la Dec. 16 at 7:26 PM
$LNAI
0 · Reply
DD_First
DD_First Dec. 14 at 4:28 PM
$LNAI As of late 2025, Lunai Bioworks (NASDAQ: LNAI) has reported several significant breakthroughs in its AI-powered therapeutic and diagnostic pipelines: Parkinson's Disease Subtyping: In December 2025, Lunai announced the identification of three clinically relevant subtypes of Parkinson's disease using its proprietary Augusta Platform. This discovery integrates large-scale proteomic data to prioritize drug targets, aiming to accelerate clinical trials in a $13 billion market. LNAI achieved complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models using its second-generation immune cell therapy. First Licensing LOI: Following the pancreatic cancer results, Lunai secured its first Letter of Intent to license its next-generation immune cell therapy. Alzheimer’s Diagnostic Improvement: In October 2025, Lunai's AI platform showed a 35% improvement in diagnostic accuracy for Alzheimer's disease by combining MRI scans with genetic and metabolic data.
1 · Reply
11thestate
11thestate Dec. 12 at 3:05 PM
Imagine buying $ENOB (Now $LNAI ) at its peak, only to watch it crash like this — and then finding out there’s a way to get some money back. To all $ENOB investors out there, we’ve got some important news for you: https://11th.com/cases/enochian-biosciences-investor-settlement
0 · Reply
StockWisher2Day
StockWisher2Day Dec. 12 at 12:18 AM
$LNAI clowns always getting in at the worst times 🤣 y'all shorts are cooked. This is called the accumulation phase
1 · Reply
MarketForecasting
MarketForecasting Dec. 11 at 8:07 PM
$LNAI short this to zero , you will see how this company is nothing but a fraud
0 · Reply
MarketForecasting
MarketForecasting Dec. 11 at 8:05 PM
$LNAI shorters are back , let’s go , this company is a scam . And should be shorted to zero
0 · Reply
JL_TradeZ
JL_TradeZ Dec. 10 at 1:10 PM
12/09 Yesterday End of Day Recap $SNTI $GIPR $LNAI $IBIO $NCPL
0 · Reply
Stengaard1
Stengaard1 Dec. 9 at 11:07 PM
$LNAI Wiettekind has filed a https://ir.lunaibioworks.com/financials/sec-filings/sec-filings-details/default.aspx?FilingId=18986089 what does it mean: Basically Wiettekind lost the case. For more details (even it is somewhat simplified) https://grok.com/share/c2hhcmQtMg_ee9d7d54-5cdf-4a7d-b621-afabdab5dd15
0 · Reply
prismmarketview
prismmarketview Dec. 9 at 4:26 PM
Lunai Bioworks (NASDAQ: $LNAI) highlighted new advancements in its AI platform, emphasizing improved model efficiency and expanded real-world deployment across enterprise customers. The update signals accelerating commercial traction as the company positions itself for broader adoption in 2026. https://prismmarketview.com/lunai-bioworks-identifies-three-parkinsons-disease-subtypes-prioritizes-new-drug-targets-to-accelerate-development/
0 · Reply
Musaad_47
Musaad_47 Dec. 9 at 3:06 PM
$LNAI
0 · Reply
Almas2025
Almas2025 Dec. 9 at 3:06 PM
$LNAI why it’s stuck!!!!
0 · Reply
MartinKruse
MartinKruse Dec. 9 at 2:48 PM
$LNAI good news and the shorters force it down again :-( This should be illigally. It would be great if so much of the stock was bought up that they were forced out and lost their investment in the stock.
2 · Reply
stockwuzet
stockwuzet Dec. 9 at 2:01 PM
$LNAI so halt at opening
0 · Reply